This article is more than 5 years old. Information may no longer be current.

STAAR Surgical submits data on EDOF lens

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

STAAR Surgical has submitted data from the European trial of its EVO+ Visian ICL with aspheric optic to DEKRA, the company’s European notified body, according to a press release.

If approved, the lens, which is designed to correct or reduce myopia or hyperopia and presbyopia, could be commercially available in the second quarter of 2020 in countries that recognize the CE mark.

“Our team is pleased to announce our EDOF lens for presbyopia met the primary performance endpoint of our multisite European pivotal clinical trial and that we have recently submitted the data to our notified body for review,” Caren Mason, president and CEO of STAAR Surgical, said in the release.

EVO Visian ICLs are implanted directly behind the iris and in front of the anterior capsule of the human crystalline lens and offer an alternative for refractive error correction.